Non-small-cell lung cancer in the elderly

Critical Reviews in Oncology/Hematology

Volumn 57, Issue 2, 2006, Pages 183-190

  Meriggi, Fausto ^a,b   Zaniboni, Alberto ^a  

^a Oncology Department   (Italy)

^b International Society of Geriatric Oncology (SIOG)   (France)

Author keywords

Chemotherapy; Elderly; NSCLC; Radiation therapy; Surgery

Indexed keywords

CARBOPLATIN; CISPLATIN; ETOPOSIDE; GEMCITABINE; NAVELBINE; PACLITAXEL; TEGAFUR;

CANCER ADJUVANT THERAPY; CANCER DIAGNOSIS; CANCER SCREENING; CANCER THERAPY; GERIATRIC ASSESSMENT; HUMAN; LIFE EXPECTANCY; LUNG NON SMALL CELL CANCER; ONCOLOGICAL PARAMETERS; QUALITY OF LIFE; REVIEW; SURVIVAL RATE;

AGED; AGED, 80 AND OVER; CARCINOMA, NON-SMALL-CELL LUNG; CLINICAL TRIALS; HUMANS; ITALY; MULTICENTER STUDIES;

EID: 31344477499     PISSN: 10408428     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.critrevonc.2005.06.004     Document Type: Review

References (74)

1. American Cancer Society Centers for Disease Control and Prevention Proceedings of the National Conference on Cancer and the Older Person Atlanta, Georgia, February 10-12 Cancer 74 1994 1995 2214
2. R. Yancik, and L.A. Ries Aging and cancer in America. Demographic and epidemiologic perspectives Hematol Oncol Clin North Am 14 2000 17 23
3. E. Silverberg, and J.A. Lubera Cancer Stat 38 1988 5 22
4. C. Gridelli, F. Perrone, and S. Monfardini Lung cancer in the elderly Eur J Cancer 33 1997 2313 2314
5. C. Gridelli, P. Maione, G. Colantoni, and A. Rossi Chemotherapy of non-small cell lung cancer in elderly patients Curr Med Chem 9 2002 1487 1495
6. L. Repetto, L. Fratino, and R.A. Audisio Comprehensive geriatric assessment adds information to Eastern Cooperative Oncology Group Performance Status in elderly cancer patients: an Italian Group for Geriatric Oncology study J Clin Oncol 20 2002 494 502
7. L.F. Hutchins, J.M. Unger, J.J. Crowley, C.A. Coltman, and K.S. Albain Underrepresentation of patients 65 years of age or older in cancer-treatment trials N Engl J Med 341 1999 2061 2067
8. The Elderly Lung Cancer Vinorelbine Italian Study Group Effects of vinorelbine on quality of life and survival of elderly patients with advanced non-small cell lung cancer J Natl Cancer Inst 85 1999 365 376
9. J.H. Schiller Current standards of care in small-cell and non-small-cell lung cancer Oncology 61 Suppl. 1 2001 3 13
10. K. Yamamoto, J. Padilla Alarcon, and V. Calvo Medina Surgical results of stage I non-small-cell lung cancer: comparison between elderly and younger patients Eur J Cardiothorac Surg 23 2003 21 25
11. J.L. Port, M. Kent, and R.J. Korst Surgical resection for lung cancer in octogenarian Chest 126 2004 733 738
12. A.R. Jazieh, M. Hussain, and J.A. Howington Prognostic factors in patients with surgically resected stages I and II non-small-cell lung cancer Ann Thorac Surg 70 2000 374 379
13. M.T. van Rens, A.B. de la Riviere, H.R. Elbers, and J.M. van Den Bosch Prognostic assessment of 2,361 patients who underwent pulmonary resection for non-small-cell lung cancer, stage I, II and IIIA Chest 117 2000 374 379
14. P.B. Bach, L.D. Cramer, D. Schrag, R.J. Downer, S.E. Gelfand, and C.B. Begg The influence of hospital volume on survival after resection for lung cancer N Engl J Med 345 2001 181 188
15. M.A. O'Rourke, J.R. Feussner, P. Feigl, and J. Laszlo Age trends of lung cancer stage at diagnosis. Implications for lung cancer screening in the elderly JAMA 258 1987 921 927
16. North-Eastern Italian Oncology Group-Neoplasms of the Elderly Committee Clinical characteristics, diagnosis and treatment of elderly patients with lung cancer at non-surgical institutions: a multicenter study Tumori 75 1990 429 433
17. M. Montella, C. Gridelli, and A. Crispo Has lung cancer in the elderly different characteristics at presentation? Oncol Rep 9 2002 1093 1096
18. G. Numico, E. Russi, and M. Merlano Best supportive care in non-small-cell lung cancer: is there a role for radiotherapy and chemotherapy? Lung Cancer 32 2001 213 226
19. T. Okamoto, R. Maruyama, and F. Shoji Clinical patterns and treatment outcome of elderly patients in clinical stage IB/II non-small cell lung cancer J Surg Oncol 87 2004 134 138
20. H.C. Fernando, A.D. Hoyos, V. Litle, C.P. Belani, and J.D. Luketich Radiofrequency ablation: identification of the ideal patient Clin Lung Cancer 6 2004 149 153
21. Non-Small Cell Lung Cancer Collaborative Group Chemotherapy in non-small cell lung cancer: a meta-analysis using updated data on individual patients from 52 randomised clinical trials Br Med J 311 1995 899 909
22. The International Adjuvant Lung Cancer Trial Collaborative Group Cisplatin-based adjuvant chemotherapy in patients with completely resected non-small-cell lung cancer N Engl J Med 350 2004 351 360
23. H. Kato, Y. Ichinose, M. Ohta for the Japan Lung Cancer Research Group on Postsurgical Adjuvant Chemotherapy A randomized trial of adjuvant chemotherapy with uracil-tegafur for adenocarcinoma of the lung N Engl J Med 350 2004 1713 1721
24. Winton TL, Livingston R, Johnson D, et al. A prospective randomised trial of adjuvant vinorelbine (VIN) and cisplatin (CIS) in completely resected stage IB and II non-small cell lung cancer (NSCLC) Intergroup JBR.10. J Clin Oncol 2004 ASCO Annual Meeting Proceedings (Post-Meeting Edition), vol. 22, No 14S (July 15 Suppl.), 2004:7018 [Abstract].
25. Strauss GM, Herndon J, Maddaus MA, et al. for CALGB, Radiation Therapy Oncology Group, and North Central Cancer Treatment Group. Randomized clinical trial of adjuvant chemotherapy with paclitaxel and carboplatin following resection in stage IB non-small cell lung cancer (NSCLC): report of Cancer and Leukemia Group B (CALGB) Protocol 9633. J Clin Oncol 2004 ASCO Annual Meeting Proceedings (Post-Meeting Edition), vol. 22, No 14S (July 15 Suppl.), 2004:7019 [Abstract].
26. K. Hotta, K. Matsuo, H. Ueoka, K. Kiura, M. Tabata, and M. Tanimoto Role of adjuvant chemotherapy in patients with resected non-small-cell lung cancer: reappraisal with a meta-analysis of controlled randomized trials J Clin Oncol 22 2004 3860 3867
27. Meta-analysis Trialist Group Post-operative radiotherapy in non-small cell lung cancer: systematic review and meta-analysis of individual patient data from nine randomized controlled trials Lancet 352 1998 257 263
28. C.J. Langer, C. Hsu, and W. Curran Do elderly patients with locally advanced non-small cell lung cancer benefit from combined modality therapy? Int J Radiat Oncol Biol Phys 51 2001 20 21
29. S.E. Schild, P.J. Stella, and S.M. Geyer The outcome of combined-modality therapy for stage III non-small-cell lung cancer in the elderly J Clin Oncol 21 2003 3201 3206
30. K. Hotta, K. Matsuo, H. Ueoka, K. Kiura, M. Tabata, and M. Tanimoto Meta-analysis of randomized clinical trials comparing cisplatin to carboplatin in patients with advanced non-small-cell lung cancer J Clin Oncol 22 2004 3852 3859
31. C. Delbaldo, S. Michiels, N. Syz, J.C. Soria, T. Le Chevalier, and J.P. Pignon Benefits of adding a drug to a single-agent or a 2-agent chemotherapy regimen in advanced non-small-cell lung cancer. A meta-analysis JAMA 292 2004 470 484
32. C. Gridelli, F. Perrone, C. Gallo for the MILES Investigators Chemotherapy for elderly patients with advanced non-small-cell lung cancer: the Multicenter Italian Lung Cancer in the Elderly Study (MILES) phase III randomized trial J Natl Cancer Inst 95 2003 362 372
33. G. Frasci, V. Lorusso, N. Panza for the Southern Italy Cooperative Oncology Group and Interregional Association for the Study Gemcitabine plus vinorelbine versus vinorelbine alone in elderly patients with non-small cell lung cancer J Clin Oncol 18 2000 2529 2536
34. C.J. Langer, J. Manola, and P. Bernardo Cisplatin-based therapy for elderly patients with advanced non-small-cell lung cancer: implications of Eastern Cooperative Oncology Group 5592, a randomized trial J Natl Cancer Inst 94 2002 173 181
35. F. Perrone, C. Gallo, and C. Gridelli Re: Cisplatin-based therapy for elderly patients with advanced non-small-cell lung cancer: implications of Eastern Cooperative Oncology Group 5592, a randomized trial JNCI 94 2002 1029 1031
36. J.R. Pereira, S.J. Martins, S.M. Nikaedo, and F.K. Ikari Chemotherapy with cisplatin and vinorelbine for elderly patients with locally or metastatic non-small-cell lung cancer (NSCLC) BMC Cancer 4 2004 69
37. L. Crinò, S. Novello, M.R. Migliorino on behalf of the Italian Lung Cancer Project Investigators A phase III randomized trial comparing three platinum-based doublets in advanced non-small cell lung cancer (NSCLC): impact of PS=2 vs. 0 or 1 and age >70 vs. <70 on chemotherapy outcome Proc Am Soc Clin Oncol 21 2002 315a [Abstract 1258]
38. R.C. Lilenbaum, J.E. Herndon II, and M.A. List Single-agent versus combination chemotherapy in advanced non-small-cell lung cancer: the Cancer and Leukemia Group B (study 9730) J Clin oncol 23 2005 190 196
39. F. Fossella, J.R. Pereira, and J. von Pawel Randomized, multinational, phase III study of docetaxel plus platinum combinations versus vinorelbine plus cisplatin for advanced non-small-cell lung cancer: the TAX 326 study group J Clin Oncol 21 2003 3016 3024
40. P. Comella, G. Frasci, and P. Carnicelli Gemcitabine with either paclitaxel or vinorelbine vs paclitaxel or gemcitabine alone for elderly or unfit advanced non-small-cell lung cancer patients Br J Cancer 91 2004 489 497
41. T.A. Marsland, D.H. Garfield, M.M. Khan, R.M. Look, K.A. Boehm, and L. Asmar Sequential versus concurrent paclitaxel and carboplatin for the treatment of advanced non-small cell lung cancer in elderly patients and patients with poor performance status: results of two phase II, multicenter trials Lung Cancer 47 2005 111 120
42. D.G. Pfister, D.H. Johnson, and C.G. Azzoli American Society of Clinical Oncology treatment of unresectable non-small-cell lung cancer guideline: update 2003 J Clin Oncol 22 2004 330 353
43. F.A. Shepherd, J. Dancey, and R. Ramlau Prospective randomized trial of docetaxel versus best supportive care in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy J Clin Oncol 18 2000 2095 2103
44. F.V. Fossella, R. DeVore, R.N. Kerr the TAX 320 Non-Small-Cell Lung Cancer Study Group Randomized phase III trial of docetaxel versus vinorelbine or ifosfamide in patients with advanced non-small-cell lung cancer previously treated with platinum-containing chemotherapy regimens J Clin Oncol 18 2000 2354 2362
45. N. Hanna, F.A. Shepherd, and F.V. Fossella Randomized phase III trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapy J Clin Oncol 22 2004 1589 1597
46. De Marinis F, Pereira JR, Park K, et al. Does second-line therapy for non-small cell lung cancer (NSCLC) result in symptom palliation? Analysis of 484 patients from a randomized trial of pemetrexed vs docetaxel. J Clin Oncol 2004 ASCO Annual Meeting Proceedings (Post-Meeting Edition), vol. 22, No 14S (July 15 Suppl.), 2004:7035 [Abstract].
47. M. Fukuoka, S. Yano, and G. Giaccone Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer J Clin Oncol 21 2003 2237 2246
48. M.G. Kris, R.B. Natale, and R.S. Herbst A phase II trial of ZD 1839 (Iressa) in advanced non-small cell lung cancer (NSCLC) patients who have failed platinum- and docetaxel-based regimen (IDEAL 2) Proc Am Soc Clin Oncol 21 2002 291a [Abstract 1166]
49. C. Gridelli, P. Maione, V. Castaldo, and A. Rossi Gefitinib in elderly and unfit patients affected by advanced non-small-cell lung cancer Br J Cancer 89 2003 1827 1829
50. F. Cappuzzo, S. Bartolini, and G.L. Ceresoli Efficacy and tolerability of gefitinib in pretreated elderly patients with advanced non-small-cell lung cancer Br J cancer 90 2004 82 86
51. B.E. Johnson, J. Lucca, and M.S. Rabin Preliminary results from a phase II study of the epidermal growth factor receptor tyrosine kinase inhibitor erlotinib in patients >70 years of age with previously untreated advanced non-small cell lung carcinoma Proc Am Soc Clin Oncol 23 2004 633 [Abstract 7080]
52. A. Haringhuizen, H. van Tinteren, Vaessen HFR, P. Baas, and N. van Zandwijk Gefitinib as a last treatment option for non-small-cell lung cancer: durable disease control in a subset of patients Ann Oncol 15 2004 786 792
53. V.A. Miller, M.G. Kris, and N. Shah Bronchioloalveolar pathologic subtype and smoking history predict sensitivity to gefitinib in advanced non-small-cell lung cancer J Clin Oncol 22 2004 1103 1109
54. Miller VA, Herbst R, Prager D, et al. Long survival of never smoking non-small cell lung cancer (NSCLC) patients (pts) treated with erlotinib HCI (OSI-774) and chemotherapy: sub-group analysis of TRIBUTE. J Clin Oncol 2004 ASCO Annual Meeting Proceedings (Post-Meeting Edition), vol. 22, No 14S (July 15 Suppl.), 2004:7061 [Abstract].
55. Kris MG, Sandler A, Miller V, et al. Cigarette smoking history predicts sensitivity to erlotinib: results of a phase II trial in patients with bronchioloalveolar carcinoma (BAC). J Clin Oncol 2004 ASCO Annual Meeting Proceedings (Post-Meeting Edition), vol. 22, No 14S (July 15 Suppl.), 2004:7062 [Abstract]
56. C. Gridelli, E. Massarelli, and P. Maione Potential role of molecularly targeted therapy in the management of advanced nonsmall cell lung carcinoma in the elderly Cancer 101 2004 1733 1744
57. G. Giaccone, R.S. Herbst, and C. Manegold Gefitinib in combination with gemcitabine and cisplatin in advanced non-small cell lung cancer: a phase III trial - INTACT 1 J Clin Oncol 22 2004 777 784
58. R.S. Herbst, G. Giaccone, and J.H. Schiller Gefitinib in combination with paclitaxel and carboplatin in advanced non-small cell lung cancer: a phase III trial - INTACT 2 J Clin Oncol 22 2004 785 794
59. U. Gatzemeier, A. Pluzanska, A. Szczesna for TALENT Study Investigators Results of a phase III trial of erlotinib (OSI-774) combined with cisplatin and gemcitabine (GC) chemotherapy in advanced non-small cell lung cancer (NSCLC) Proc Am Soc Clin Oncol 22 2004 617 [Abstract 7010]
60. R.S. Herbst, D. Prager, and R. Hermann TRIBUTE - A phase III trial of erlotinib HCI (OSI-774) combined with carboplatin and paclitaxel (CP) chemotherapy in advanced non-small cell lung cancer (NSCLC) Proc Am Soc Clin Oncol 22 2004 617 [Abstract 7011]
61. J.M. de Rijke, L.J. Schouten, and GP.M. ten Velde Influence of age, comorbidity and performance status on the choice of treatment for patients with non-small cell lung cancer; results of a population-based study Lung Cancer 46 2004 233 245
62. K. Hotta, H. Ueoka, K. Kiura, M. Tabata, and M. Tanimoto An overview of 48 elderly-specific clinical trials of systemic chemotherapy for advanced non-small cell lung cancer Lung Cancer 46 2004 61 76
63. S.D. Ramsey, N. Howlander, R.D. Etzioni, and B. Donato Chemotherapy use, outcomes, and costs for older persons with advanced non-small-cell lung cancer: evidence from surveillance, epidemiology and end results-medicare J Clin Oncol 22 2004 4971 4978
64. L. Repetto, A. Venturino, and L. Fratino Geriatric oncology: a clinical approach to the older patient with cancer Eur J Cancer 39 2003 870 880
65. D. Saliba, M. Elliott, and L.Z. Rubenstein The Vulnerable Elders Survey: a tool for identifying vulnerable older people in the community J Am Geriatr Soc 49 2001 1691 1699
66. S.M. Lichtman, and G. Villani Chemotherapy in the elderly: pharmacologic considerations Cancer Control 7 2000 548 556
67. M. Extermann, H. Chen, and A.B. Cantor Predictors of tolerance to chemotherapy in older patients: a prospective pilot study Eur J Cancer 38 2002 1466 1473
68. B.T. Hennessy, E.O. Hanrahan, and O.S. Breathnach Chemotherapy options for the elderly patient with advanced non-small cell lung cancer Oncologist 6 2003 270 277
69. C. Gridelli, C. Manegold, and P. Mali Oral Vinorelbine given as monotherapy to advanced, elderly NSCLC patients: a multicentre phase II trial Eur J Cancer 40 2004 2424 2431
70. A. Hurria, and M.G. Kris Management of lung cancer in older adults CA Cancer J Clin 53 2003 325 341
71. P.D. Makrantonakis, E. Galani, and P.G. Harper Non-small cell lung cancer in the elderly Oncologist 9 2004 556 560
72. K. Kelly, S. Giarritta, and S. Hayes Should older patients (pts) receive combination chemotherapy for advanced stage non-small-cell lung cancer (NSCLC)? An analysis of Southwest Oncology Trials 9509 and 9308 Proc Am Soc Clin Oncol 20 2001 329a [Abstract 1313]
73. C. Bokemeyer, M.S. Aapro, and A. Courdi EORTC guidelines for the use of erythropoietic proteins in anaemic patients with cancer Eur J Cancer 40 2004 2201 2216
74. J.D. Rizzo, A.E. Lichtin, and S.H. Woolf Use of Epoetin in patients with cancer: evidence-based clinical practice guidelines of the American Society of Clinical Oncology and the American Society of Hematology J Clin Oncol 20 2002 4083 4107